TD Cowen Downgrades 2Seventy Bio Inc. (TSVT) to Market Perform, 'Takeout Uncertain'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. EXPE
3. ARM
4. FIS
5. BROS
6. QCOM
7. DDOG
8. EW
9. ZG
10. W

Go back to TD Cowen Downgrades 2Seventy Bio Inc. (TSVT) to Market Perform, 'Takeout Uncertain'

Regeneron (REGN) Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio (TSVT) Platforms and Preclinical and Clinical Programs

January 30, 2024 7:02 AM EST

(Updated - January 30, 2024 7:03 AM EST)

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio, Inc. to acquire full development and commercialization rights to its pipeline of investigational novel immune cell therapies, along with its discovery and clinical manufacturing capabilities. 2seventy bio employees who support the acquired programs will join Regeneron Cell Medicines, a newly formed research & development (R&D) unit to advance cell therapies and combination approaches in oncology and immunology.

Regeneron and 2seventy share a relentless... More

2seventy bio (TSVT) Announces Cost Cuts, Will Focus on Abecma

January 30, 2024 7:02 AM EST

2seventy bio, Inc. (Nasdaq: TSVT), announced today that it is transforming the Company to focus exclusively on the commercialization and development of Abecma (idecabtagene vicleucel), its BCMA-targeted CAR T therapy for multiple myeloma. The actions announced today follow an extensive evaluation of the Companys business and strategic alternatives by its Board of Directors. As a... More